查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401961

2030 年胰臟癌市场预测：按癌症类型、治疗类型、诊断、癌症分期、受影响部位、最终用户和地区进行的全球分析

Pancreatic Cancer Market Forecasts to 2030 - Global Analysis By Type, Treatment Type, Diagnosis, Stage of Cancer, Affected Area, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球胰臟癌市场规模为 29 亿美元，预计预测期内复合年增长率为 15.6%，到 ​​2030 年将达到 81 亿美元。

胰臟癌是一种影响胰臟的恶性，胰臟是位于胃后方的重要器官。当胰臟中的细胞不受控制地生长和分裂，形成肿瘤时，就会发生这种类型的癌症。它可以迅速转移到附近的器官或身体的远处部位，使治疗变得困难。胰臟癌的症状包括腹痛、体重减轻、黄疸、消化不良和疲倦。

根据美国癌症协会估计，到 2023 年，预计将有约 64,050 人被诊断出患有胰腺癌，约 50,550 人将死于胰腺癌。

胰臟癌发生率增加

癌症发病率正在迅速增加，原因包括不健康的用餐、缺乏运动、吸烟和饮酒、空气污染和缺乏体力活动。由于癌症病例的特定年龄累积以及修復机制随着年龄的增长而变得不那么有效，癌症病例的发生率急剧增加。此外，被认为是癌症危险因子的慢性感染疾病正在增加，特别是在低收入和中等收入国家。因此，发病率上升是拉动市场需求的重要因素。

治疗费用高

高治疗成本是胰臟癌市场的主要威胁。胰臟癌的治疗包括放射线治疗、化疗、手术和支持性治疗，而且可能很昂贵。由于治疗费用高昂，患者难以获得治疗，这可能会对获得及时有效的治疗产生负面影响。然而，治疗的经济负担阻碍了患者接受必要的身体检查和选择建议的治疗方法。这可能导致诊断延迟、治疗方法选择次优和治疗结果不佳。

临床研究增加

流行病学和基础临床研究的增加正在导致预防、诊断和治疗方面的改善。研究人员继续揭示胰臟癌背后复杂的分子和遗传机制，为创新治疗方法铺路。此外，对新药物研发标靶、生物标记和个人化医疗策略的探索证明胰臟癌研究正在不断发展。因此，增加临床研究是胰臟癌治疗的机会。

副作用

胰臟癌治疗在治疗期间和治疗后会产生各种副作用，这取决于患者。化疗是最常见的癌症治疗方法，其作用是杀死胰臟中的癌细胞，但它也会消除体内的健康细胞，这会对患者的健康产生负面影响，并导致副作用復发。此外，用于治疗癌症的放射线治疗具有皮肤发红、噁心和食慾不振等副作用。在极少数情况下，辐射暴露甚至会导致腹泻。因此，胰臟癌治疗的副作用阻碍了市场的成长。

COVID-19 的影响

COVID-19大流行对胰臟癌市场产生了重大影响。这场大流行导致癌症筛检、诊断和治疗计划以及其他常规卫生服务的延迟。由于限制、资源重新分配以及医疗保健重点转向大流行管理，胰腺癌患者在获得及时护理方面面临障碍。此外，临床试验和研究活动也受到影响，减缓了新治疗方法和治疗方法的进展。

预计化疗领域在预测期内将是最大的

化疗部分估计占最大占有率。化疗变得越来越流行，因为它具有阻止癌症扩散、杀死癌细胞、减缓疾病生长以及使用强力化学物质杀死快速生长的细胞等优点。它变得越来越普遍。此外，在胰臟癌的任何阶段都使用化疗来杀死癌细胞，并在诊断和恢復期间重复给药药物。此外，胰臟癌的化疗可以在手术期间进行，也可以与放射线治疗结合。

预计诊所领域在预测期内的复合年增长率最高。

预计诊所业务在预测期内将出现良好成长。专科诊所和癌症中心发展的主要驱动力是真正的治疗与优质服务的结合。由于肿瘤科医生和医疗保健专业人员共用相同的身份和专业知识，因此临床人员的可用性是专科诊所的优势，使患者能够轻鬆且经济地接受诊断和治疗。专科诊所仅提供专门的医疗服务，例如为癌症患者提供癌症中心，更容易管理保险和患者时间表，并利用癌症治疗的最新进展。

占有率最大的地区：

在估计期间，亚太地区占据最大的市场占有率。该地区人口众多且正在迅速扩张，导致胰臟癌的高盛行率。吸烟、肥胖和糖尿病等危险因素的流行进一步增加了该地区的疾病负担。此外，亚太地区癌症治疗的可近性和卫生基础设施的品质都在改善。包括影像和分子测试在内的先进诊断技术的出现，改善了胰臟癌的早期检测和诊断。这改善了患者的治疗效果并增加了该地区对诊断服务的需求。

复合年增长率最高的地区：

预计北美在预测期内将实现盈利成长。北美胰臟癌盛行率很高，是研究、诊断和治疗进展的关键地区。该地区强大的研究基础设施和资助机会在了解疾病和开发标靶治疗方面取得了长足进展。此外，北美拥有完善的医疗保健系统，可以获得专门的医疗服务和先进的治疗选择。

免费客製化服务：

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球胰臟癌市场：依类型

  • 介绍
  • 胰臟神经内分泌肿瘤
  • 胰臟腺癌

第六章全球胰臟癌市场：依治疗类型

  • 介绍
  • 免疫疗法
  • 外科手术
  • 化疗
  • 荷尔蒙治疗
  • 标靶药物治疗
  • 放射治疗
  • 其他治疗类型

第七章全球胰臟癌市场：依诊断分类

  • 介绍
  • 电脑断层扫描 (CT) 扫描
  • 验血
  • 正子断层扫描 (PET) 扫描
  • 超音波
  • 磁振造影(MRI)
  • 切片检查
  • 其他诊断

第八章全球胰臟癌市场：依癌症阶段划分

  • 介绍
  • 阶段
  • 局部进行性
  • 转移性

第九章全球胰臟癌市场：依受影响地区

  • 介绍
  • 内分泌
  • 外分泌

第 10 章 全球胰臟癌市场：依最终用户分类

  • 介绍
  • 医院
  • 诊断实验室
  • 研究
  • 其他最终用户

第十一章全球胰臟癌市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司简介

  • Diffusion Pharmaceuticals
  • Novartis International AG
  • Amgen, Inc.
  • Pharmacyte Biotech Inc.
  • Polaris Pharmaceuticals, Inc.
  • Clovis Oncology
  • OncoGenex Pharmaceuticals Inc.
  • Oncolytics Biotech
  • Sun BioPharma, Inc.
  • Eli Lilly and Company
  • Midatech Pharma PLC
  • F. Hoffmann-La Roche AG
  • Celgene Corporation
Product Code: SMRC24481

According to Stratistics MRC, the Global Pancreatic Cancer Market is accounted for $2.9 billion in 2023 and is expected to reach $8.1 billion by 2030 growing at a CAGR of 15.6% during the forecast period. Pancreatic cancer is a malignant neoplasm affecting the pancreas, a crucial organ located behind the stomach. This type of cancer occurs when cells in the pancreas undergo uncontrolled growth and division, forming a tumor. It can spread rapidly to nearby organs and distant sites in the body, making it challenging to treat. Symptoms of pancreatic cancer may include abdominal pain, weight loss, jaundice, digestive problems, and fatigue.

According to o the America's Cancer Society for pancreatic cancer, about 64,050 people will be diagnosed with pancreatic cancer in 2023 and estimation of around 50,550 people will die of pancreatic cancer.

Market Dynamics:

Driver:

Rising incidence of pancreatic cancer

There is a rapid increase in the prevalence of cancer cases, and its growth is driven by factors such as an unhealthy diet, physical inactivity, tobacco and alcohol consumption, air pollution, and physical inactivity. The incidence of cancer cases rises dramatically due to the buildup of cancer cases specific to age and the less effective repair mechanisms that become less effective as the person grows older. Furthermore, there are a growing number of chronic infections that are thought to be risk factors for cancer cases, primarily in countries with low or middle incomes. Therefore, rising incidence is a significant factor propelling market demand.

Restraint:

High treatment costs

High treatment costs pose a significant threat to the pancreatic cancer market. Treatment for pancreatic cancer may be expensive and include radiation therapy, chemotherapy, surgery, and supportive care. Patients may find it difficult to afford or obtain treatment due to its high cost, which may negatively impact their capacity to get timely and effective care. However, the financial burden of treatment can deter patients from seeking necessary medical attention or opting for recommended treatment options. This can lead to delays in diagnosis, suboptimal treatment choices, and poorer treatment outcomes.

Opportunity:

Rise in clinical research

The increase in epidemiologic and basic clinical research is leading to improved prevention, diagnosis, and treatment. Researchers are continuously unravelling the complex molecular and genetic mechanisms underlying pancreatic cancer, paving the way for innovative treatment modalities. Moreover, the exploration of new drug targets, biomarkers, and personalized medicine strategies is a testament to the evolving landscape of pancreatic cancer research. Therefore, a rise in clinical research is a good opportunity for pancreatic cancer treatment.

Threat:

Side effects

Pancreatic cancer treatments have various side effects during and after the treatment, depending on the patient. The most common cancer treatment, chemotherapy, works to kill cancerous cells in the pancreas but also eliminates healthy cells from the body, which has a negative impact on health and the recurrence of side effects in patients. Additionally, there are certain adverse effects from radiation therapy used to treat cancer, like skin reddening, nausea, and appetite loss. In rare instances, even diarrhoea is caused by radiation exposure. Therefore, the side effects of pancreatic cancer treatment impede the growth of the market.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the pancreatic cancer market. The pandemic caused delays in cancer screenings, diagnoses, and treatment plans, among other routine healthcare services. Patients with pancreatic cancer faced hurdles in accessing timely medical care due to restrictions, reallocation of resources, and a shift in healthcare priorities toward managing the pandemic. Moreover, clinical trials and research activities were also affected, which slowed down the progress of new treatment modalities and therapeutic advancements.

The chemotherapy segment is expected to be the largest during the forecast period

The chemotherapy segment is estimated to hold the largest share. Chemotherapy is becoming increasingly common due to benefits like stopping cancer from spreading, killing cancer cells, slowing the growth of the disease, and using strong chemicals to kill rapidly growing cells. Moreover, chemotherapy is used in any stage of pancreatic cancer to kill the cancer cells, and the drugs are administered in cycles with an alternating period of diagnosis and recovery. Additionally, chemotherapy for pancreatic cancer can be given during surgery or in conjunction with radiation therapy.

The clinics segment is expected to have the highest CAGR during the forecast period

The clinics segment is anticipated to have lucrative growth during the forecast period. The primary drivers of the growth of specialty clinics or cancer centers are genuine treatment combined with high-quality services. The availability of clinical staff members is a benefit of specialty clinics because oncologists and medical professionals share the same entity and specialization, and the patient can easily and affordably receive a diagnosis and treatment. Specialty clinics only offer specialized types of medicine, such as cancer centers for cancer patients, making it easier to manage insurance, patient scheduling, and access to the most recent advancements in cancer treatment.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The region has a sizable and quickly expanding population, which raises the prevalence of pancreatic cancer cases. The prevalence of risk factors such as smoking, obesity, and diabetes further adds to the disease burden in this region. Furthermore, access to cancer treatment and the quality of healthcare infrastructure have both improved in the Asia-Pacific region. The availability of advanced diagnostic technologies, including imaging modalities and molecular testing, has enhanced the early detection and diagnosis of pancreatic cancer. This has led to improved patient outcomes and an increased demand for diagnostic services in this region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America has a high prevalence of pancreatic cancer, making it a crucial region for research, diagnosis, and treatment advancements. Considerable progress has been made in the understanding of the disease and the development of targeted therapies due to the region's strong research infrastructure and funding opportunities. Furthermore, North America has a well-established healthcare system that provides access to specialized healthcare services and advanced treatment options.

Key players in the market:

Some of the key players in the Pancreatic Cancer Market include Diffusion Pharmaceuticals, Novartis International AG, Amgen, Inc., Pharmacyte Biotech Inc., Polaris Pharmaceuticals, Inc., Clovis Oncology, OncoGenex Pharmaceuticals Inc., Oncolytics Biotech, Sun BioPharma, Inc., Eli Lilly and Company, Midatech Pharma PLC, F. Hoffmann-La Roche AG and Celgene Corporation.

Key Developments:

In Oct 2023, Sun Pharma and Zydus Life sciences announced that they have entered into a licensing agreement to co-market Desidustat, an oral treatment for anaemia associated with Chronic Kidney Disease (CKD) in India.

In Jan 2022, Novartis announced collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for Bio Medical Research, potentially leading to development of a treatment designed to promote the re growth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

Types Covered:

  • Pancreatic Neuroendocrine Tumors
  • Pancreatic Adenocarcinoma

Treatment Types Covered:

  • Immunotherapy
  • Surgery
  • Chemotherapy
  • Hormone Therapy
  • Targeted Drug Therapy
  • Radiation Therapy
  • Other Treatment Types

Diagnosis Covered:

  • Computerized Tomography (CT) Scans
  • Blood Test
  • Positron Emission Tomography (PET) Scans
  • Ultrasound
  • Magnetic Resonance Imaging (MRI)
  • Biopsy
  • Other Diagnosis

Stage of Cancers Covered:

  • Early Stage
  • Locally Advanced
  • Metastatic

Affected Areas Covered:

  • Endocrine
  • Exocrine

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Research Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pancreatic Cancer Market, By Type

  • 5.1 Introduction
  • 5.2 Pancreatic Neuroendocrine Tumors
  • 5.3 Pancreatic Adenocarcinoma

6 Global Pancreatic Cancer Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Immunotherapy
  • 6.3 Surgery
  • 6.4 Chemotherapy
  • 6.5 Hormone Therapy
  • 6.6 Targeted Drug Therapy
  • 6.7 Radiation Therapy
  • 6.8 Other Treatment Types

7 Global Pancreatic Cancer Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 Computerized Tomography (CT) Scans
  • 7.3 Blood Test
  • 7.4 Positron Emission Tomography (PET) Scans
  • 7.5 Ultrasound
  • 7.6 Magnetic Resonance Imaging (MRI)
  • 7.7 Biopsy
  • 7.8 Other Diagnosis

8 Global Pancreatic Cancer Market, By Stage of Cancer

  • 8.1 Introduction
  • 8.2 Early Stage
  • 8.3 Locally Advanced
  • 8.4 Metastatic

9 Global Pancreatic Cancer Market, By Affected Areas

  • 9.1 Introduction
  • 9.2 Endocrine
  • 9.3 Exocrine

10 Global Pancreatic Cancer Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Diagnostic Laboratories
  • 10.4 Research Laboratories
  • 10.5 Other End Users

11 Global Pancreatic Cancer Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Diffusion Pharmaceuticals
  • 13.2 Novartis International AG
  • 13.3 Amgen, Inc.
  • 13.4 Pharmacyte Biotech Inc.
  • 13.5 Polaris Pharmaceuticals, Inc.
  • 13.6 Clovis Oncology
  • 13.7 OncoGenex Pharmaceuticals Inc.
  • 13.8 Oncolytics Biotech
  • 13.9 Sun BioPharma, Inc.
  • 13.10 Eli Lilly and Company
  • 13.11 Midatech Pharma PLC
  • 13.12 F. Hoffmann-La Roche AG
  • 13.13 Celgene Corporation

List of Tables

  • Table 1 Global Pancreatic Cancer Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Pancreatic Cancer Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Pancreatic Cancer Market Outlook, By Pancreatic Neuroendocrine Tumors (2021-2030) ($MN)
  • Table 4 Global Pancreatic Cancer Market Outlook, By Pancreatic Adenocarcinoma (2021-2030) ($MN)
  • Table 5 Global Pancreatic Cancer Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 6 Global Pancreatic Cancer Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 7 Global Pancreatic Cancer Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 8 Global Pancreatic Cancer Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 9 Global Pancreatic Cancer Market Outlook, By Hormone Therapy (2021-2030) ($MN)
  • Table 10 Global Pancreatic Cancer Market Outlook, By Targeted Drug Therapy (2021-2030) ($MN)
  • Table 11 Global Pancreatic Cancer Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 12 Global Pancreatic Cancer Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 13 Global Pancreatic Cancer Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 14 Global Pancreatic Cancer Market Outlook, By Computerized Tomography (CT) Scans (2021-2030) ($MN)
  • Table 15 Global Pancreatic Cancer Market Outlook, By Blood Test (2021-2030) ($MN)
  • Table 16 Global Pancreatic Cancer Market Outlook, By Positron Emission Tomography (PET) Scans (2021-2030) ($MN)
  • Table 17 Global Pancreatic Cancer Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 18 Global Pancreatic Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2021-2030) ($MN)
  • Table 19 Global Pancreatic Cancer Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 20 Global Pancreatic Cancer Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 21 Global Pancreatic Cancer Market Outlook, By Stage of Cancer (2021-2030) ($MN)
  • Table 22 Global Pancreatic Cancer Market Outlook, By Early Stage (2021-2030) ($MN)
  • Table 23 Global Pancreatic Cancer Market Outlook, By Locally Advanced (2021-2030) ($MN)
  • Table 24 Global Pancreatic Cancer Market Outlook, By Metastatic (2021-2030) ($MN)
  • Table 25 Global Pancreatic Cancer Market Outlook, By Affected Areas (2021-2030) ($MN)
  • Table 26 Global Pancreatic Cancer Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 27 Global Pancreatic Cancer Market Outlook, By Exocrine (2021-2030) ($MN)
  • Table 28 Global Pancreatic Cancer Market Outlook, By End User (2021-2030) ($MN)
  • Table 29 Global Pancreatic Cancer Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 30 Global Pancreatic Cancer Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 31 Global Pancreatic Cancer Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 32 Global Pancreatic Cancer Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.